Having won the most acquisitive crown in 2016, Stryker seems to be seeking the prize this year too, buying Invuity and spinal company K2M.
Extending a pulmonary hypertension drug’s lifecycle could help battle generic erosion, but investors might have been looking for a more transformative deal.
With its latest acquisition Emergent Biosolutions is tapping into new ways to access public spending.
Dexcom can capitalise on its new algorithm technology, but is now enmeshed in a tangled web of partnerships.
Pfizer is to push Exact’s cancer test in a deal that could “permanently alter the trajectory of Cologuard”.
Immunocore has recently been beset with multiple senior executive departures, but has managed to press on into phase I with a Glaxo-partnered asset.
The two companies disagree on the commercial potential of an mRNA flu vaccine, and Biontech just got Pfizer’s buy-in.
The Australian group has found a partner for its lead asset at last, so why is the stock down?
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.